Clinical trials: Irritable Bowel Syndrome
Irritable Bowel Syndrome
Long Term Safety Study of Plecanatide
Multi-center, open-label, long-term safety study
- Trial name
- IBS-C (NCT02706483)
- Testing
- Plecanatide
- Where
- 204 sites in United States
- Volunteers
- 2,272 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Bloating, Digestive Discomfort
A Clinical Trial to Examine the Effects of Gut Health Supplements to Improve Gut and Digestive Health and Function
This is a double-blind, randomized, placebo-controlled trial evaluating the efficacy of JSHealth's Debloat \& Detox supplement, used alone or in combination with their Probiotics supplement, on gut and digestive health and…
- Conditions
- Bloating, Digestive Discomfort, Irritable Bowel Syndrome (IBS), Flatulence
- Trial name
- NCT07902882
- Testing
- Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- JS Health & Vitamins
Irritable Bowel Syndrome
Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS
Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome.
- Trial name
- NCT05348642
- Testing
- pasteurized A. muciniphila
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- A-Mansia Biotech S.A.
Fibromyalgia
Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia
Fibromyalgia is a medical disorder characterized by chronic widespread pain, and a heightened and painful response to pressure. Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term…
- Trial name
- L2009-03 (NCT01469936)
- Testing
- PERMEAPROTECT
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Lescuyer Laboratory
Irritable Bowel Syndrome
Diarrhea Predominant Irritable Bowel Syndrome in Females
Clinical Trial with TRN-002 in Women with Irritable Bowel Syndrome (IBS) The purpose of this study is to investigate the safety and effectiveness of a new investigational drug in women for the treatment of diarrhea-predominant…
- Trial name
- NCT00461526
- Testing
- crofelemer
- Where
- 43 sites in United States
- Volunteers
- 240 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of abdominal pain/discomfort associated with irritable bowel disease.
- Trial name
- NCT00139672
- Testing
- PD-217,014
- Volunteers
- 330 people
- Sponsor
- Pfizer
Irritable Bowel Syndrome
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts.
- Trial name
- BALANCE (NCT07519395)
- Testing
- Camlipixant
- Where
- 114 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
IBS (Irritable Bowel Syndrome)
Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms
A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in…
- Trial name
- DORPHI (NCT06889779)
- Testing
- MIX 1, MIX 2
- Where
- 12 sites in India
- Volunteers
- 353 people
- Sponsor
- dsm-firmenich Switzerland AG
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation
GOS to Reduce Symptom Severity in IBS
IBS is a highly prevalent bowel disorder, characterized by recurrent abdominal pain during bowel movements or a change in bowel habits.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome - Constipation, Irritable Bowel Syndrome - Diarrhoea, Irritable Bowel Syndrome - Mixed
- Trial name
- EGIS (NCT05157061)
- Testing
- Galacto-oligosaccharides (GOS), Maltodextrine
- Where
- 9 sites in Belgium, Netherlands and 1 more
- Volunteers
- 153 people
- Sponsor
- Clasado
Patients With Irritable Bowel Syndrome With Diarrhea
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
This trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase II clinical trial. Its purpose is to evaluate the efficacy and safety of Huanghou Zhixie Diwan in subjects with irritable bowel…
- Trial name
- NCT07721012
- Testing
- Huanghou Zhixie Diwan group, Huanghou Zhixie Diwan mimic
- Where
- 14 sites in China
- Volunteers
- 120 people
- Sponsor
- Lei Yunshang Group
Irritable Bowel Syndrome With Diarrhea (IBS-D)
G-PUR® for Symptomatic Treatment in Irritable Bowel Syndrome With Diarrhea
A randomized, double-blind, placebo-controlled pilot study in patients with IBS-D according to Rome IV criteria evaluating the clinical efficacy and safety of oral administration of 2g G-PUR® tid compared to placebo in a cohort…
- Trial name
- NCT04138186
- Testing
- 2.0g G-PUR®, oral administration
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Glock Health, Science and Research GmbH
Irritable Bowel Syndrome (IBS)
Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients
This is an open labeled, one-armed real-world study in IBS-patients. All participants will receive active treatment for 12 weeks.
- Trial name
- GRIPS (NCT03550742)
- Testing
- Fuco-N-Tetraose
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Glycom, Inc.
Irritable Bowel Syndrome
Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy
The Purpose of the study is to determine the efficacy of Kleen Enema® (Phosphate Enema) for bowel preparation in out-patients under going sigmoidoscopy procedure and to evaluate the safety behavior of Kleen Enema® in outpatients…
- Trial name
- NCT02386904
- Testing
- Phosphate Enema (Kleen® Enema)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome (IBS)
Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
This study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation
- Trial name
- NCT00584298
- Testing
- SMS995
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis
Irritable Bowel Syndrome With Constipation (IBS-C)
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the efficacy and safety of ASP0456 in patients with constipation predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT02316899
- Testing
- linaclotide
- Where
- 61 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Inc
Irritable Colon
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).
- Trial name
- NCT00101985
- Testing
- talnetant
- Where
- 135 sites in United States, Australia and 8 more
- Volunteers
- 741 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
This FTIH study is designed to assess the safety, tolerability and pharmacokinetic (PK) of escalating single and repeat oral doses of GSK3352589 in normal healthy volunteers.
- Trial name
- NCT03154086
- Testing
- GSK3352589
- Where
- Australia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline